Join us for a discussion led by James S. Manuso, Ph.D., past Chairman & CEO of Astex Pharmaceuticals. This presentation will review successes and failures of strategy, organization architecture and political engagement in the course of the development and growth of Astex Pharmaceuticals, from its foundation as SuperGen (formerly Supergenerics) in 1991 to 2013, when it was sold to Otsuka Pharmaceuticals for $886MM. A specific focus of the presentation will be on the period, 2003-2013, during which time a strategy of product approvals and targeted domestic and international acquisitions and divestitures of companies, compounds and discovery operations was executed, enabled by a series of financings and the revenue streams emanating from Nipent for Hairy Cell Leukemia and the approvals of Dacogen for Myelodysplastic Syndrome and AML.

The lessons learned from this decade-long process of corporate development will be addressed, along with their potential applicability to the challenges faced by many biopharma organizations today.